{"Clinical Trial ID": "NCT00470847", "Intervention": ["INTERVENTION 1:", "Lapatinib, Brain radiation, Herceptin", "\u2022 Lapatinib before and during whole brain radiotherapy (WBRT), then Herceptin 4mg/kg IV weekly"], "Eligibility": ["Incorporation criteria:", "Invasive breast cancer confirmed histologically or cytologically", "HER2 overexpressing breast cancer defined as 3+ coloration by immunohistochemistry, or HER2 genetic amplification by FISH", "At least one parenchymic brain metastasis", "The progression of the disease in the CNS as evaluated by at least one of the following; new neurological signs or symptoms; new CNS lesions in an imaging study; progressive lesions in an imaging study", "At least two weeks since previous radiation therapy, last chemotherapy, immunotherapy, biological therapy or major surgery for cancer", "- 18 years or older", "\u2022 Life expectancy greater than 12 weeks", "ECOG Performance Status 0-2", "Normal function of the organ and marrow as described in the protocol", "Left ventricular ejection fraction > 50%", "\u2022 Capable of swallowing and conserving oral medicines", "- Exclusion criteria:", "Previous WBRT", "\u2022 Reception of any other research officer", "Concomitant chemotherapy, immunotherapy, biological therapy or hormone therapy for the treatment of their cancer", "History of Grade 3 or 4 allergic reactions attributed to compounds of chemical or biological composition similar to herceptin or lapatinib", "Leptomeninge carcinomasis as the only CNS involvement site", "- Concomitant treatment with medicinal products that induce CYP3A4 inhibitors", "\u2022 Malabsorption syndrome, disease significantly affecting gastrointestinal function, stomach resection, small intestine or active ulcerative colitis", "History of immediate or delayed hypersensitivity reaction to gadolinium contrast agents", "Other contraindications known to MRI", "\u2022 Uncontrolled intercurrent disease", "\u2022 History of other active malignancies, with the exception of basal cell carcinoma or squamous skin carcinoma, or in situ cervix carcinoma", "Pregnant or lactating women"], "Results": ["Performance measures:", "The maximum tolerated dose of Lapatinib associated with cranial radiation in patients with CNS metastases from positive HER2 breast cancer.", "The maximum tolerated dose is defined as:The maximum dose of a drug or treatment that does not cause unacceptable side effects.", "Calendar: 5 years", "Results 1:", "Title of the arm/group: Lapatinib, Brain Radiation of Holes, Herceptin", "Description of the arm/group: Lapatinib before and during whole brain radiotherapy (WBRT), then Herceptin 4mg/kg IV weekly", "Total number of participants analysed: 35", "Type of measurement: Number", "Unit of measurement: milligrams 1250"], "Adverse Events": ["Undesirable Events 1:", "Total: 8/27 (29.63%)", "Diarrhoea 2/27 (7.41%)", "Vomiting 2/27 (7.4%)", "Hypoxia 1/27 (3.70 per cent)", "Sinusitis 1/27 (3.70%)", "Pulmonary embolism 2/27 (7.4%)"]}